

CDK1 Antibody (Y15) Blocking Peptide
Synthetic peptide
Catalog # BP7517e**Specification**

CDK1 Antibody (Y15) Blocking Peptide - Product InformationPrimary Accession [P06493](#)**CDK1 Antibody (Y15) Blocking Peptide - Additional Information****Gene ID** 983**Other Names**

Cyclin-dependent kinase 1, CDK1, Cell division control protein 2 homolog, Cell division protein kinase 1, p34 protein kinase, CDK1, CDC2, CDC28A, CDKN1, P34CDC2

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7517e](/products/AP7517e) was selected from the Y15 region of human CDK1 Antibody (Y15). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CDK1 Antibody (Y15) Blocking Peptide - Protein Information**Name** CDK1**Synonyms** CDC2, CDC28A, CDKN1, P34CDC2**Function**

Plays a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle as well as mitotic onset; promotes G2-M transition via association with multiple interphase cyclins (PubMed: [2344612](http://www.uniprot.org/citations/2344612), PubMed: [2188730](http://www.uniprot.org/citations/2188730), PubMed: [16407259](http://www.uniprot.org/citations/16407259), PubMed: [17459720](http://www.uniprot.org/citations/17459720), PubMed: [16933150](http://www.uniprot.org/citations/16933150), PubMed: [18356527](http://www.uniprot.org/citations/18356527), PubMed: [19509060](http://www.uniprot.org/citations/19509060)),

PubMed:20171170,
PubMed:19917720,
PubMed:20937773,
PubMed:20935635,
PubMed:21063390,
PubMed:23355470,
PubMed:23601106,
PubMed:23602554,
PubMed:25556658,
PubMed:26829474,
PubMed:30139873,
PubMed:30704899).
Phosphorylates PARVA/actopaxin, APC, AMPH, APC, BARD1, Bcl-xL/BCL2L1, BRCA2, CALD1, CASP8,
CDC7, CDC20, CDC25A, CDC25C, CC2D1A, CENPA, CSNK2 proteins/CKII, FZR1/CDH1, CDK7,
CEBPB, CHAMP1, DMD/dystrophin, EEF1 proteins/EF-1, EZH2, KIF11/EG5, EGFR, FANCG, FOS, GFAP,
GOLGA2/GM130, GRASP1, UBE2A/hHR6A, HIST1H1 proteins/histone H1, HMGA1, HIVEP3/KRC,
KAT5, LMNA, LMNB, LBR, LATS1, MAP1B, MAP4, MARCKS, MCM2, MCM4, MKLP1, MLST8, MYB,
NEFH, NFIC, NPC/nuclear pore complex, PITPNM1/NIR2, NPM1, NCL, NUCKS1, NPM1/numatrin,
ORC1, PRKAR2A, EEF1E1/p18, EIF3F/p47, p53/TP53, NONO/p54NRB, PAPOLA, PLEC/plectin, RB1,
TPPP, UL40/R2, RAB4A, RAP1GAP, RCC1, RPS6KB1/S6K1, KHDRBS1/SAM68, ESPL1, SKI,
BIRC5/survivin, STIP1, TEX14, beta-tubulins, MAPT/TAU, NEDD1, VIM/vimentin, TK1, FOXO1,
RUNX1/AML1, SAMHD1, SIRT2, CGAS and RUNX2 (PubMed:2344612, PubMed:2188730, PubMed:16407259, PubMed:17459720, PubMed:16933150, PubMed:18356527, PubMed:19509060, PubMed:20171170, PubMed:19917720, PubMed:20937773, PubMed:20935635, PubMed:21063390, PubMed:23355470, PubMed:23601106, PubMed:23602554, PubMed:25556658, PubMed:32351706, PubMed:26829474, PubMed:30704899, PubMed:34741373).
CDK1/CDC2-cyclin-B controls pronuclear union in interphase fertilized eggs (PubMed:18480403, PubMed:20360007). Essential for
early stages of embryonic development (PubMed:18480403, PubMed:20360007). During G2
and early mitosis, CDC25A/B/C-mediated dephosphorylation activates CDK1/cyclin complexes
which phosphorylate several substrates that trigger at least centrosome separation, Golgi
dynamics, nuclear envelope breakdown and chromosome condensation (PubMed:2344612, PubMed:2188730, PubMed:18480403, PubMed:20360007, PubMed:30139873). Once
chromosomes are condensed and aligned at the metaphase plate, CDK1 activity is switched off by

WEE1- and PKMYT1-mediated phosphorylation to allow sister chromatid separation, chromosome decondensation, reformation of the nuclear envelope and cytokinesis (PubMed:18480403, PubMed:20360007). Phosphorylates KRT5 during prometaphase and metaphase (By similarity). Inactivated by PKR/EIF2AK2- and WEE1-mediated phosphorylation upon DNA damage to stop cell cycle and genome replication at the G2 checkpoint thus facilitating DNA repair (PubMed:20360007). Reactivated after successful DNA repair through WIP1-dependent signaling leading to CDC25A/B/C-mediated dephosphorylation and restoring cell cycle progression (PubMed:20395957). Catalyzes lamin (LMNA, LMNB1 and LMNB2) phosphorylation at the onset of mitosis, promoting nuclear envelope breakdown (PubMed:2344612, PubMed:2188730, PubMed:37788673). In proliferating cells, CDK1-mediated FOXO1 phosphorylation at the G2-M phase represses FOXO1 interaction with 14-3-3 proteins and thereby promotes FOXO1 nuclear accumulation and transcription factor activity, leading to cell death of postmitotic neurons (PubMed:18356527). The phosphorylation of beta-tubulins regulates microtubule dynamics during mitosis (PubMed:16371510). NEDD1 phosphorylation promotes PLK1-mediated NEDD1 phosphorylation and subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation (PubMed:19509060). In addition, CC2D1A phosphorylation regulates CC2D1A spindle pole localization and association with SCC1/RAD21 and centriole cohesion during mitosis (PubMed:20171170). The phosphorylation of Bcl-xL/BCL2L1 after prolonged G2 arrest upon DNA damage triggers apoptosis (PubMed:19917720). In contrast, CASP8 phosphorylation during mitosis prevents its activation by proteolysis and subsequent apoptosis (PubMed:20937773). This phosphorylation occurs in cancer cell lines, as well as in primary breast tissues and lymphocytes (PubMed:20937773). EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing (PubMed:20935635). CALD1 phosphorylation promotes Schwann cell migration during peripheral nerve regeneration (By similarity). CDK1-cyclin-B complex phosphorylates NCKAP5L and mediates its dissociation from centrosomes during mitosis (PubMed:26549230). Regulates the amplitude of the cyclic expression of the core clock gene BMAL1 by phosphorylating its transcriptional repressor NR1D1, and this phosphorylation is necessary for SCF(FBXW7)- mediated ubiquitination and proteasomal degradation of NR1D1 (PubMed:27238018). Phosphorylates EML3 at 'Thr-881' which is essential for its interaction with HAUS augmin-like complex and TUBG1 (PubMed:30723163). Phosphorylates CGAS during mitosis, leading to its inhibition, thereby preventing CGAS activation by self DNA during mitosis (PubMed:32351706).

Cellular Location

Nucleus {ECO:0000250|UniProtKB:P11440}. Cytoplasm {ECO:0000250|UniProtKB:P11440}. Mitochondrion. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, spindle. Note=Cytoplasmic during the interphase Colocalizes with SIRT2 on centrosome during prophase and on spindle fibers during metaphase of the mitotic cell cycle. Reversibly translocated from cytoplasm to nucleus when phosphorylated before G2-M transition when associated with cyclin-B1. Accumulates in mitochondria in G2-arrested cells upon

DNA-damage

Tissue Location

[Isoform 2]: Found in breast cancer tissues.

CDK1 Antibody (Y15) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CDK1 Antibody (Y15) Blocking Peptide - Images

CDK1 Antibody (Y15) Blocking Peptide - Background

CDK1 is a member of the Ser/Thr protein kinase family. This protein is a catalytic subunit of the highly conserved protein kinase complex known as M-phase promoting factor (MPF), which is essential for G1/S and G2/M phase transitions of eukaryotic cell cycle. Mitotic cyclins stably associate with this protein and function as regulatory subunits. The kinase activity of this protein is controlled by cyclin accumulation and destruction through the cell cycle. The phosphorylation and dephosphorylation of this protein also play important regulatory roles in cell cycle control.

Transcript Variant: This variant (1) encodes the full length isoform.

CDK1 Antibody (Y15) Blocking Peptide - References

Kramer, A., et al., Nat. Cell Biol. 6(9):884-891 (2004). Dai, X., et al., J. Invest. Dermatol. 122(6):1356-1364 (2004). Litvak, V., et al., Mol. Cell 14(3):319-330 (2004). Shapira, M., et al., Cancer 100(8):1615-1621 (2004). Chow, J.P., et al., J. Biol. Chem. 278(42):40815-40828 (2003).